MDG1021
Solid Tumors
PreclinicalActive
Key Facts
About Medigene
Medigene is a clinical-stage biotech focused on engineering T-cell receptor (TCR)-modified T-cell therapies for solid tumors, a notoriously difficult-to-treat area. Its strategy is built on two proprietary technology pillars: a high-throughput TCR discovery platform and a PD1-41BB costimulatory switch receptor designed to enhance T-cell persistence and function. The company has advanced its lead candidate, MDG1011, into Phase I/II clinical trials and is actively building a pipeline of novel TCRs through internal discovery and partnerships. As a publicly traded entity, Medigene aims to validate its platform and establish a leadership position in the evolving TCR-T cell therapy landscape.
View full company profileTherapeutic Areas
Other Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| APVO603 | Aptevo Therapeutics | Preclinical |
| APVO711 | Aptevo Therapeutics | Preclinical |
| Platform-derived Immunotherapy | GenCirq | Pre-clinical |
| SP-2-225 | Shuttle Pharmaceuticals | Preclinical |
| SP-1-161 | Shuttle Pharmaceuticals | Preclinical |
| HBM1020 | Harbour BioMed | Phase 1 |
| HBM7022 | Harbour BioMed | Phase 1 |
| HBM9033 | Harbour BioMed | Discovery |
| Undisclosed Whole Cell Vaccine Program(s) | Neuvogen | Pre-clinical |
| SY-5609 | Syros Pharmaceuticals | Phase 1/2 |
| Not Specified (TCR Therapy) | T-Cure Bioscience | Phase 1 |
| B7-H3 Program | Ocean Biomedical | Discovery |